Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zai Lab Ltd ADR (ZLAB)

Zai Lab Ltd ADR (ZLAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,595,590
  • Shares Outstanding, K 110,328
  • Annual Sales, $ 398,990 K
  • Annual Income, $ -257,100 K
  • EBIT $ -268 M
  • EBITDA $ -260 M
  • 60-Month Beta 1.04
  • Price/Sales 9.02
  • Price/Cash Flow N/A
  • Price/Book 4.44

Options Overview Details

View History
  • Implied Volatility 53.48% ( +2.75%)
  • Historical Volatility 84.98%
  • IV Percentile 13%
  • IV Rank 39.58%
  • IV High 127.18% on 06/17/24
  • IV Low 5.20% on 09/17/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 32
  • Volume Avg (30-Day) 86
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 5,754
  • Open Int (30-Day) 6,229

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.41
  • Number of Estimates 2
  • High Estimate -0.39
  • Low Estimate -0.44
  • Prior Year -0.82
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.60 +17.37%
on 05/08/25
34.59 -6.33%
on 04/23/25
-0.13 (-0.40%)
since 04/22/25
3-Month
24.24 +33.66%
on 04/10/25
39.77 -18.53%
on 03/28/25
-1.38 (-4.09%)
since 02/21/25
52-Week
16.01 +102.37%
on 08/13/24
39.77 -18.53%
on 03/28/25
+12.24 (+60.71%)
since 05/22/24

Most Recent Stories

More News
Zai Lab Flat as China Okays Application

Zai Lab Limited (NASDAQ: ZLAB) shares barely moved Monday, on word China’s National Medical Products ...

ZLAB : 32.51 (-0.25%)
NovoCure Q4 EPS Misses, Revenue Matches

NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.

NVCR : 18.09 (+1.92%)
MRK : 77.82 (+1.09%)
ZLAB : 32.51 (-0.25%)
RHHBY : 39.3350 (-0.14%)
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?

The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances...

NVCR : 18.09 (+1.92%)
ZLAB : 32.51 (-0.25%)
Novocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment Surges

The trial met its primary endpoint, showing a statistically significant improvement in median overall survival.

NVCR : 18.09 (+1.92%)
ZLAB : 32.51 (-0.25%)
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77%

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Although death rates for some cancers are declining, the world is facing a sharp increase in cancer...

ONCY : 0.4019 (-4.54%)
ZNTL : 1.2300 (+1.65%)
TIL : 24.68 (+52.16%)
IMRX : 1.4700 (-0.68%)
ZLAB : 32.51 (-0.25%)
ONC.TO : 0.56 (-3.45%)
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END

ONCY : 0.4019 (-4.54%)
NTBL : 0.2479 (-27.68%)
JNJ : 152.66 (-0.34%)
ZLAB : 32.51 (-0.25%)
ONC.TO : 0.56 (-3.45%)
CRDF : 2.88 (-0.69%)
Why Wall Street Thinks This Artificial Intelligence (AI) Stock Could Skyrocket 140% Over the Next 12 Months

Cathie Wood and Bill Gates like this stock, too.

ARKG : 20.82 (+0.53%)
ZLAB : 32.51 (-0.25%)
SDGR : 21.24 (+3.56%)
Qiming Venture Partners' portfolio company Tuhu Car Successfully Listed on the Hong Kong Stock Exchange

/PRNewswire/ -- Qiming Venture Partners' portfolio company Tuhu Car, China's leading one-stop car service platform, successfully listed on the Hong Kong Stock...

ZLAB : 32.51 (-0.25%)
SDGR : 21.24 (+3.56%)
BILI : 18.35 (+0.71%)
ZH : 4.02 (+2.55%)
Why Shares of Zai Lab Limited Were Jumping on Tuesday

Zai Lab's shares benefited from positive clinical trial news.

GMAB : 21.01 (+2.39%)
ZLAB : 32.51 (-0.25%)
SGEN : 228.74 (-0.07%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB). Such investors are...

ZLAB : 32.51 (-0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China....

See More

Key Turning Points

3rd Resistance Point 34.32
2nd Resistance Point 33.77
1st Resistance Point 33.18
Last Price 32.51
1st Support Level 32.04
2nd Support Level 31.49
3rd Support Level 30.90

See More

52-Week High 39.77
Last Price 32.51
Fibonacci 61.8% 30.69
Fibonacci 50% 27.89
Fibonacci 38.2% 25.09
52-Week Low 16.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar